Using the CCR2 antagonist RS504393 in our in vivo studies (Fig. 5A), we found that combining RS504393 with cisplatin significantly reduced tumor volume and mass in F. nucleatum-infected mice compared to cisplatin alone (P = 0.0011 and 0.0075) (Fig. 5B and C), demonstrating the anti-resistance effect of CCR2 blockade. The gene discussed is CCR2; the disease is neoplasm.